Copyright © 1990 by the European Society of Cardiology.
© 1990 The European Society of Cardiology
Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy
H{circumflex}pital Cardiologique Pessac, France
Received 6 December 1989; revised 13 July 1989; .
Correspondence to Professor J. Bricad. Hopital Cardiologique, Avenue de Magellan, 33604 Pessac. France.
Abstract
Trimetazidine (TMZ) has been shown to have anti-ischaemic properties improving exercise tolerance without haemodynamic efects. A 6-month double-blindplacebo-controlledstudy was carried out in 20patients, mean age 59 ± 6 years, to examine the benefit of adding 60 mg of TMZ vsplacebo to the classical therapy, excluding those previously treated with calcium-antagonists, conversion enzyme inhibitors, vasodilators and antiplatelet agents. All patients had severe ischaemic cardiomyopathy, confirmed by coronary angiography; six were in N YHA class IV; 14 in N YHA class III; four had mild recurrent angina pectoris. The assessment included clinical and biological evaluation, electrocardiography (ECG) ,24-h ECG monitoring, cardiac volwne evaluation with chest X-ray, left ventricular fractional shortening by echocardiography, left ventricular ejection, fraction by radionuclide angiography. Baseline characteristics were similar inplacebo(1 I patients) and TMZ(ninepatients) groups. Eighteen patients (nine in eachgroup) were followed up for 6 months. In eight patients of the placebo group, treatment had to be modified (addition of calcium antagonists: four patients, conversion enzyme inhibitors: two patients; digitalics: one patient; diuretics: one patient). In the TMZ group, digitalic therapy was withdrawn in one patient and added in one patient ( P < 0.01). At 6 months, all TMZ group patients were free from angina; dyspnoea was improved in all TMZ patients and in only one placebo patient (P < 0.001). Ejection fraction, increased by 9.3% in the TMZ group and decreased by 15.6% in the placebo group (P < 0.018), CV decreased by 7% with TMZ, increased by 4% with placebo. (P = 0.034). TMZ seemsto improve clinical status; ejection fraction and cardiac volume without adverse effects in patients with severe ischaemic cardiomyopathy
Key Words: Ischaemic cardiomyopathy • trimetazidine
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Ashrafian, M. P. Frenneaux, and L. H. Opie Metabolic Mechanisms in Heart Failure Circulation, July 24, 2007; 116(4): 434 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Fragasso, A. Palloshi, P. Puccetti, C. Silipigni, A. Rossodivita, M. Pala, G. Calori, O. Alfieri, and A. Margonato A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart Failure J. Am. Coll. Cardiol., September 5, 2006; 48(5): 992 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Fragasso, G. Perseghin, F. De Cobelli, A. Esposito, A. Palloshi, G. Lattuada, P. Scifo, G. Calori, A. Del Maschio, and A. Margonato Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure Eur. Heart J., April 2, 2006; 27(8): 942 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Morrow and M. M. Givertz Modulation of Myocardial Energetics: Emerging Evidence for a Therapeutic Target in Cardiovascular Disease Circulation, November 22, 2005; 112(21): 3218 - 3221. [Full Text] [PDF]
|
|
|
|
 |
|
 P Di Napoli, A A Taccardi, and A Barsotti Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy Heart, February 1, 2005; 91(2): 161 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V K Khoury, B Haluska, J Prins, and T H Marwick Effects of glucose-insulin-potassium infusion on chronic ischaemic left ventricular dysfunction Heart, January 1, 2003; 89(1): 61 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.V. Cokkinos Can metabolic manipulation reverse myocardial dysfunction? Eur. Heart J., December 1, 2001; 22(23): 2138 - 2139. [PDF]
|
|
|
|
|
|
R. Belardinelli and A. Purcaro Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy Eur. Heart J., December 1, 2001; 22(23): 2164 - 2170. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Inci, A. Dutly, V. Rousson, A. Boehler, and W. Weder Trimetazidine protects the energy status after ischemia and reduces reperfusion injury in a rat single lung transplant model J. Thorac. Cardiovasc. Surg., December 1, 2001; 122(6): 1155 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.L. Chierchia Trimetazidine and left ventricular ischaemic dysfunction: an overview of clinical evidence Eur. Heart J. Suppl., November 1, 2001; 3(suppl_O): O16 - O20. [Abstract] [PDF]
|
|